Objective:To document the outcome of patients treated with barbiturate coma
for severe symptomatic angioplasty-resistant vasospasm. To compare mortali
ty with that predicted by admission APACHE II score, and neurological outco
me with that of historical controls treated with barbiturate coma for vasos
pasm, and with historical controls with delayed ischaemic deficits from vas
ospasm treated with nimodipine.
Design: Cohort study.
Setting: Neurosurgical Intensive Care Unit of tertiary referral university
teaching hospital.
Patients: Eleven (6.7 %) of 164 consecutive patients with aneurysmal SAH ma
naged according to our protocol who were treated with thiopentone-induced b
urst suppression coma for severe symptomatic, angioplasty-resistant vasospa
sm.
Interventions: Chart, database and literature review.
Measurements and results: All 11 patients survived to hospital discharge (m
ortality 0 %) compared with first-day APACHE II predicted mortality of 30.6
% (p = 0.15). Outcome at 6 months was: good recovery 8/11 (72.7 %), modera
te disability 2/11 (18.2 %), vegetative survival 1/11 (9.1 %), Ten of 11 (9
0.9 %) had a good neurological outcome compared with 50.6 % of historical c
ontrols with delayed ischaemic deficit from vasospasm (odds ratio 9.78, 95
% confidence interval 1.24-77.0, p = 0.02, and 0 % of previously reported p
atients treated with barbiturate coma for vasospasm (p < 0.01).
Conclusion: Our results are better than previously published outcomes and s
uggest formal evaluation of barbiturate coma in the treatment of severe res
istant symptomatic vasospasm following SAI;I is warranted.